C4 Therapeutics Presents Cemsidomide Phase 1/1b Myeloma Biomarker Data
Question
C4 Therapeutics Presents Cemsidomide Phase 1/1b Myeloma Biomarker Data
Direct answer
Positive translational oncology data strengthens degrader platform validation, supporting commercial partnership valuation. — bullish pressure on CCCC via biotech pipeline derisking via validated Phase 1 biomarker mechanisms.
- Original publisher
- Market Ontology
- Evidence through
- 2026-09-26
- Published
- 2026-10-20
- Revision
- 1 · 2026-10-20
Cite as: Market Ontology, “C4 Therapeutics Presents Cemsidomide Phase 1/1b Myeloma Biomarker Data”, revision 1, evidence through 2026-09-26. https://marketontology.com/catalysts/2026-09-26/c4-therapeutics-presents-cemsidomide-phase-1-1b-myeloma-biomarker-data-75ac53
| Asset | Direction | Timeframe | Channel | Score |
|---|---|---|---|---|
| CCCC | ▲Bull | 1–5 days | biotech pipeline derisking via validated Phase 1 biomarker mechanisms | 51 |
| PFE | ▲Bull | 1–4 weeks | combination therapy efficacy expansion for ELREXFIO franchise | 47 |
C4 Therapeutics Presents Cemsidomide Phase 1/1b Myeloma Biomarker Data
Positive translational oncology data strengthens degrader platform validation, supporting commercial partnership valuation. — bullish pressure on CCCC via biotech pipeline derisking via validated Phase 1 biomarker mechanisms.
Presented positive biomarker and T-cell activation data at 23rd IMS Annual Meeting.
- SourcePresented positive biomarker and T-cell activation data at 23rd IMS Annual Meeting.
- TransmissionPositive translational oncology data strengthens degrader platform validation, supporting commercial partnership valuation.
- SummaryC4 Therapeutics unveiled clinical trial data at the IMS Annual Meeting. Cemsidomide showed robust immune and T-cell activation in multiple myeloma. Combinations include dexamethasone and Pfizer's elranatamab.
- CCCCDirect directional exposure
Illustrative, not advice
- Crowded positioning may already reflect the move
- Counter-catalyst could neutralize the thesis before window closes
- CCCC closes below pre-catalyst level on rising volume
- Catalyst narrative is officially walked back or contradicted
- Cross-asset confirmation (rates / FX / vol) reverses direction
- CCCC price vs. pre-event level
- CCCC volume vs. 20-day average
C4 Therapeutics Presents Cemsidomide Phase 1/1b Myeloma Biomarker Data
Positive translational oncology data strengthens degrader platform validation, supporting commercial partnership valuation. — bullish pressure on PFE via combination therapy efficacy expansion for ELREXFIO franchise.
C4 testing combination of cemsidomide with Pfizer's elranatamab.
- SourceC4 testing combination of cemsidomide with Pfizer's elranatamab.
- TransmissionPositive translational oncology data strengthens degrader platform validation, supporting commercial partnership valuation.
- SummaryC4 Therapeutics unveiled clinical trial data at the IMS Annual Meeting. Cemsidomide showed robust immune and T-cell activation in multiple myeloma. Combinations include dexamethasone and Pfizer's elranatamab.
- PFEDirect directional exposure
Illustrative, not advice
- Crowded positioning may already reflect the move
- Counter-catalyst could neutralize the thesis before window closes
- PFE closes below pre-catalyst level on rising volume
- Catalyst narrative is officially walked back or contradicted
- Cross-asset confirmation (rates / FX / vol) reverses direction
- PFE price vs. pre-event level
- PFE volume vs. 20-day average
What happened next
| Asset | Call | Base close | +1 day | +5 days | +20 days |
|---|---|---|---|---|---|
| CCCC | Bullishdisagreed | 2.98 2026-09-25 | +4.53% | -1.01% | Pending |
Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.
Sources
- C4 Therapeutics Presents New Biomarker Data from Cemsidomide Phase 1 Trial · conference_presentation · 2026-09-25
Related catalysts
- 2026-09-28Fed Chair Warsh Signals Sustained Higher Rates to Combat InflationDGS10 PFE
- 2026-09-28Fed Chair Warsh Signals Sustained Higher Rates to Combat InflationPFE
- 2026-09-28Fed Chair Warsh Signals Sustained Higher Rates to Combat InflationPFE
- 2026-09-26UN member states gather in New York to press for pandemic preparedness declarationEMBI MRNA PFE
- 2026-09-26C4 Therapeutics presents cemsidomide Phase 1 biomarker data at IMSCCCC PFE-1.01%
- 2026-09-26C4 Therapeutics Presents Cemsidomide Multiple Myeloma Phase 1 Biomarker DataCCCC-1.01%
- 2026-09-25Pfizer and NVIDIA Form $80M Joint Venture in AI-Driven Vaccine DiscoveryDNA NVDA PFE+3.95%
- 2026-09-25Pfizer and Nvidia Back $80M AI Computational Immunology VentureNVDA PFE+3.95%
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.